文献速递肥胖与代谢综合征糖尿病

达西胰高血糖素有效缓解减重术后餐后低血糖:一项随机双盲安慰剂对照交叉试验

Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
PubMed 文献 · Diabetes Care · 2022-01-01

该随机双盲安慰剂对照交叉试验纳入10例经持续葡萄糖监测证实的Roux-en-Y胃旁路术后餐后低血糖患者,比较皮下注射安慰剂或80 μg或200 μg达西胰高血糖素的效果。与安慰剂相比,两种剂量均升高最低血浆葡萄糖并减少低血糖时间。单次给药有效缓解餐后低血糖。

要点

  • 达西胰高血糖素80 μg和200 μg均较安慰剂升高最低血浆葡萄糖。
  • 两种剂量均减少血浆葡萄糖<3.9 mmol/L的时间70.0分钟。
  • 单次皮下注射达西胰高血糖素可缓解减重术后餐后低血糖。

核心结论

  • 单次给予达西胰高血糖素可有效缓解减重术后餐后低血糖。

研究设计与样本

  • 随机双盲安慰剂对照交叉试验纳入10例Roux-en-Y胃旁路术后且经持续葡萄糖监测证实餐后低血糖的参与者,随机分配至3个试验日,每个试验日进行240分钟标准化液体混合餐试验并皮下注射安慰剂或80 μg或200 μg达西胰高血糖素。

主要发现

  • 与安慰剂相比,80 μg和200 μg达西胰高血糖素均升高最低血浆葡萄糖:安慰剂3.0 ± 0.2 mmol/L(均值±标准误),80 μg组3.9 ± 0.3 mmol/L(P = 0.002),200 μg组4.5 ± 0.2 mmol/L(P = 0.0002)。
  • 与安慰剂相比,80 μg和200 μg达西胰高血糖素均减少血浆葡萄糖<3.9 mmol/L的时间70.0分钟(P = 0.030和P = 0.008)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy and safety of dasiglucagon, a novel stable glucagon analog in a liquid formulation, in Roux-en-Y gastric bypass (RYGB)-operated individuals suffering from postbariatric hypoglycemia (PBH). RESEARCH DESIGN AND METHODS: In a randomized, double-blind, placebo-controlled, crossover trial, 10 RYGB-operated participants with continuous glucose monitoring-verified PBH were randomly assigned to 3 trial days, each consisting of a 240-min standardized liquid mixed-meal test with the subcutaneous injection of placebo or 80 μg or 200 μg dasiglucagon. RESULTS: Compared with placebo, treatment with both 80 and 200 μg dasiglucagon raised nadir plasma glucose (PG) (placebo: 3.0 ± 0.2 mmol/L [mean ± SEM]; 80 μg dasiglucagon: 3.9 ± 0.3 mmol/L, P = 0.002; 200 μg dasiglucagon: 4.5 ± 0.2 mmol/L, P = 0.0002) and reduced time in hypoglycemia (PG <3.9 mmol/L) by 70.0 min (P = 0.030 and P = 0.008). CONCLUSIONS: Single-dose administration of dasiglucagon effectively mitigated postprandial hypoglycemia.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Nielsen CK, Øhrstrøm CC, Kielgast UL, et al. Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Diabetes Care. 2022. PMID: 35320361. doi:10.2337/dc21-2252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。